Cyclosporine (Vevye)
Small molecule
Evidence outlook
Approved: Dry Eye Disease
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (1)
- Vevizye (ciclosporin 0.1% eye drops solution, CyclASol / Vevye) for moderate to severe dry eye disease in adults not responding to tear substitutes
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT02617667 NCT02617667 · Dry Eye Disease Patients were randomized, and the CyclASol and vehicle groups were blinded, but the registry posts no statistical test for either primary endpoint. Corneal staining improved slightly more with CyclASol than with vehicle, while dryness scores improved more with vehicle, so it cannot be shown that the primary goals were met. Registry: NCT02617667 | 2 | Change From Baseline (Visit 1) in Total Corneal Fluorescein Staining at 113 Days (Baseline to 113 Days); Change From Baseline (Visit 1) in Dryness Severity Visual Analog Scale (VAS) at 113 Days (Baseline to 113 Days) 2016-07 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
View 1 more trial
NCT04523129 NCT04523129 · Dry Eye Disease Registry: NCT04523129 | 3 | Change From Baseline in Total Corneal Fluorescein Staining (baseline and 1 month [day 29]); Change From Baseline in Eye Dryness Score (baseline and 1 month [day 29]) 2021-09-03 | Completed. Key figures are not recorded here. | not yet graded | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (2)
What this study did
What this study did
Phase 2/3 (1)
What this study did
Phase 2 (1)
What this study did
Phase 1 (1)
What this study did
Phase 4 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Early phase / not applicable (1)
What this study did
Competitive landscape
Other Calcineurin drugs
Voclosporin, Extended-release tacrolimus (VI-0106), nanosomal tacrolimus. Compare all 4 Calcineurin drugs
3 other tracked programmes target this mechanism, none of them ahead of this one.
This drug's own stage for Dry Eye Disease: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Cyclosporine (Vevye): this drug | Approved | Small molecule | Calcineurin | Partial signal | No reviewed efficacy summary in this indication | |
| Voclosporin (Lupkynis) | Approved(overall) | Small molecule | Calcineurin, Cyclophilin A (leading to calcineurin inhibition) | Reliable signal(overall) | No reviewed efficacy summary in this indication | |
| Extended-Release Tacrolimus (VI-0106) | Phase 3(overall) | Small molecule | Calcineurin | not yet graded(overall) | No reviewed efficacy summary in this indication | |
| PL9643 | Phase 3 | Peptide | Melanocortin receptors | Partial signal | NCT05201170: Co-primary sign endpoint (lissamine green staining) did not achieve statistical significance; in the unadjusted planned analyses neither co-primary reached significance missed | |
| Reproxalap | Phase 3 | Small molecule | Reactive aldehyde species (RASP) | not yet graded | No reviewed efficacy summary in this indication | |
| Nanosomal Tacrolimus | Phase 2(overall) | Small molecule | Calcineurin | not yet graded(overall) | No reviewed efficacy summary in this indication |
Upcoming events
(4 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Cyclosporine (Vevye) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.